1
|
Rafiee Z, García-Serrano AM, Duarte JMN. Taurine Supplementation as a Neuroprotective Strategy upon Brain Dysfunction in Metabolic Syndrome and Diabetes. Nutrients 2022; 14:1292. [PMID: 35334949 PMCID: PMC8952284 DOI: 10.3390/nu14061292] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 02/07/2023] Open
Abstract
Obesity, type 2 diabetes, and their associated comorbidities impact brain metabolism and function and constitute risk factors for cognitive impairment. Alterations to taurine homeostasis can impact a number of biological processes, such as osmolarity control, calcium homeostasis, and inhibitory neurotransmission, and have been reported in both metabolic and neurodegenerative disorders. Models of neurodegenerative disorders show reduced brain taurine concentrations. On the other hand, models of insulin-dependent diabetes, insulin resistance, and diet-induced obesity display taurine accumulation in the hippocampus. Given the possible cytoprotective actions of taurine, such cerebral accumulation of taurine might constitute a compensatory mechanism that attempts to prevent neurodegeneration. The present article provides an overview of brain taurine homeostasis and reviews the mechanisms by which taurine can afford neuroprotection in individuals with obesity and diabetes. We conclude that further research is needed for understanding taurine homeostasis in metabolic disorders with an impact on brain function.
Collapse
Affiliation(s)
- Zeinab Rafiee
- Department of Experimental Medical Science, Faculty of Medicine, Lund University, 22100 Lund, Sweden; (Z.R.); (A.M.G.-S.)
- Wallenberg Centre for Molecular Medicine, Lund University, 22100 Lund, Sweden
| | - Alba M. García-Serrano
- Department of Experimental Medical Science, Faculty of Medicine, Lund University, 22100 Lund, Sweden; (Z.R.); (A.M.G.-S.)
- Wallenberg Centre for Molecular Medicine, Lund University, 22100 Lund, Sweden
| | - João M. N. Duarte
- Department of Experimental Medical Science, Faculty of Medicine, Lund University, 22100 Lund, Sweden; (Z.R.); (A.M.G.-S.)
- Wallenberg Centre for Molecular Medicine, Lund University, 22100 Lund, Sweden
| |
Collapse
|
2
|
Oja SS, Saransaari P. Properties of Taurine Release in Glucose-Free Media in Hippocampal Slices from Developing and Adult Mice. JOURNAL OF AMINO ACIDS 2015; 2015:254583. [PMID: 26347028 PMCID: PMC4540997 DOI: 10.1155/2015/254583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 07/21/2015] [Indexed: 11/20/2022]
Abstract
The release of preloaded [(3)H]taurine from hippocampal slices from developing 7-day-old and young adult 3-month-old mice was studied in a superfusion system in the absence of glucose. These hypoglycemic conditions enhanced the release at both ages, the effect being markedly greater in developing mice. A depolarizing K(+) concentration accentuated the release, which indicates that it was partially mediated by exocytosis. The anion channel blockers were inhibitory, witnessing the contribution of ion channels. NO-generating agents fomented the release as a sign of the participation of excitatory amino acid receptors. The other second messenger systems were apparently less efficient. The much greater taurine release could be a reason for the well-known greater tolerance of developing nervous tissue to lack of glucose.
Collapse
Affiliation(s)
- Simo S. Oja
- Medical School, 33014 University of Tampere, Finland
| | | |
Collapse
|
3
|
Oja SS, Saransaari P. Taurine and epilepsy. Epilepsy Res 2013; 104:187-94. [DOI: 10.1016/j.eplepsyres.2013.01.010] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Revised: 12/19/2012] [Accepted: 01/18/2013] [Indexed: 10/27/2022]
|
4
|
Oja SS, Saransaari P. Regulation of Taurine Release in the Hippocampus of Developing and Adult Mice. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013; 775:135-43. [DOI: 10.1007/978-1-4614-6130-2_11] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
5
|
Oja SS, Saransaari P. Modulation of taurine release in glucose-free media by glutamate receptors in hippocampal slices from developing and adult mice. Amino Acids 2012; 44:533-42. [DOI: 10.1007/s00726-012-1368-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2012] [Accepted: 07/12/2012] [Indexed: 12/23/2022]
|
6
|
|
7
|
Saransaari P, Oja SS. Mechanisms of Inhibitory Amino Acid Release in the Brain Stem Under Normal and Ischemic Conditions. Neurochem Res 2010; 35:1948-56. [DOI: 10.1007/s11064-010-0265-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/08/2010] [Indexed: 12/23/2022]
|
8
|
Modulation of taurine release in ischemia by glutamate receptors in mouse brain stem slices. Amino Acids 2009; 38:739-46. [DOI: 10.1007/s00726-009-0278-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2008] [Accepted: 03/11/2009] [Indexed: 10/21/2022]
|
9
|
Janáky R, Shaw CA, Oja SS, Saransaari P. Taurine release in developing mouse hippocampus is modulated by glutathione and glutathione derivatives. Amino Acids 2007; 34:75-80. [PMID: 17701096 PMCID: PMC2814815 DOI: 10.1007/s00726-007-0587-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2007] [Accepted: 07/08/2007] [Indexed: 11/24/2022]
Abstract
Glutathione (reduced form GSH and oxidized form GSSG) constitutes an important defense against oxidative stress in the brain, and taurine is an inhibitory neuromodulator particularly in the developing brain. The effects of GSH and GSSG and glycylglycine, gamma-glutamylcysteine, cysteinylglycine, glycine and cysteine on the release of [(3)H]taurine evoked by K+-depolarization or the ionotropic glutamate receptor agonists glutamate, kainate, 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-D-aspartate (NMDA) were now studied in slices from the hippocampi from 7-day-old mouse pups in a perfusion system. All stimulatory agents (50 mM K(+), 1 mM glutamate, 0.1 mM kainate, 0.1 mM AMPA and 0.1 mM NMDA) evoked taurine release in a receptor-mediated manner. Both GSH and GSSG significantly inhibited the release evoked by 50 mM K+. The release induced by AMPA and glutamate was also inhibited, while the kainate-evoked release was significantly activated by both GSH and GSSG. The NMDA-evoked release proved the most sensitive to modulation: L-Cysteine and glycine enhanced the release in a concentration-dependent manner, whereas GSH and GSSG were inhibitory at low (0.1 mM) but not at higher (1 or 10 mM) concentrations. The release evoked by 0.1 mM AMPA was inhibited by gamma-glutamylcysteine and cysteinylglycine, whereas glycylglycine had no effect. The 0.1 mM NMDA-evoked release was inhibited by glycylglycine and gamma-glutamylcysteine. In turn, cysteinylglycine inhibited the NMDA-evoked release at 0.1 mM, but was inactive at 1 mM. Glutathione exhibited both enhancing and attenuating effects on taurine release, depending on the glutathione concentration and on the agonist used. Both glutathione and taurine act as endogenous neuroprotective effectors during early postnatal life.
Collapse
Affiliation(s)
- R Janáky
- Brain Research Center, University of Tampere Medical School, Tampere, Finland
| | | | | | | |
Collapse
|
10
|
Saransaari P, Oja SS. Characteristics of taurine release in slices from adult and developing mouse brain stem. Amino Acids 2006; 31:35-43. [PMID: 16680399 DOI: 10.1007/s00726-006-0290-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2005] [Accepted: 01/17/2006] [Indexed: 10/24/2022]
Abstract
Taurine has been thought to function as a regulator of neuronal activity, neuromodulator and osmoregulator. Moreover, it is essential for the development and survival of neural cells and protects them under cell-damaging conditions. Taurine is also involved in many vital functions regulated by the brain stem, including cardiovascular control and arterial blood pressure. The release of taurine has been studied both in vivo and in vitro in higher brain areas, whereas the mechanisms of release have not been systematically characterized in the brain stem. The properties of release of preloaded [(3)H]taurine were now characterized in slices prepared from the mouse brain stem from developing (7-day-old) and young adult (3-month-old) mice, using a superfusion system. In general, taurine release was found to be similar to that in other brain areas, consisting of both Ca(2+)-dependent and Ca(2+)-independent components. Moreover, the release was mediated by Na(+)-, Cl(-)-dependent transporters operating outwards, as both Na(+)-free and Cl(-) -free conditions greatly enhanced it. Cl(-) channel antagonists and a Cl(-) transport inhibitor reduced the release at both ages, indicating that a part of the release occurs through ion channels. Protein kinases appeared not to be involved in taurine release in the brain stem, since substances affecting the activity of protein kinase C or tyrosine kinase had no significant effects. The release was modulated by cAMP second messenger systems and phospholipases at both ages. Furthermore, the metabotropic glutamate receptor agonists likewise suppressed the K(+)-stimulated release at both ages. In the immature brain stem, the ionotropic glutamate receptor agonists N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) potentiated taurine release in a receptor-mediated manner. This could constitute an important mechanism against excitotoxicity, protecting the brain stem under cell-damaging conditions.
Collapse
Affiliation(s)
- P Saransaari
- Tampere Brain Research Center, Medical School, University of Tampere, Tampere, Finland.
| | | |
Collapse
|
11
|
Fujita T, Shimada A, Wada M, Miyakawa S, Yamamoto A. Functional Expression of Taurine Transporter and its Up-Regulation in Developing Neurons from Mouse Cerebral Cortex. Pharm Res 2006; 23:689-96. [PMID: 16550472 DOI: 10.1007/s11095-006-9745-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2005] [Accepted: 12/15/2005] [Indexed: 11/25/2022]
Abstract
PURPOSE In the present study, we investigate the characteristics of taurine transport in primary cultures of neurons from mouse cerebral cortex to understand the possibility that taurine might attenuate the effects of central nervous system drugs. METHODS Primary cultured neurons from mouse cerebral cortex were used to determine the transport characteristics of taurine. The expression of taurine transporter (TAUT) in mouse neurons was determined by use of reverse transcriptase-polymerase chain reaction and Western blotting. RESULTS In vitro transport of taurine in mouse cerebrocortical neurons at day 9 was Na+-dependent and saturable with a Michaelis-Menten constant (Kt) of 10.6 +/- 4.1 microM and a maximum velocity (Vmax) of 6.68 +/- 0.85 nmol/mg protein/10 min. Na+ and Cl- activation kinetics revealed that the Na+-to-Cl(-)-to-taurine stoichiometry was 2:1:1. Na+-dependent [3H]-taurine transport was competitively inhibited by beta-alanine with an inhibitory constant (Ki) of 47.4 +/- 6.5 microM. Gamma-aminobutyric acid also inhibited Na+-dependent [3H]-taurine transport with relatively low affinity (Ki = 273 +/- 71 microM). TAUT mRNA was detected in mouse primary cultured neurons, and TAUT protein was also expressed at approximately 70 kDa. Na+-dependent taurine transport activity was increased with developing neurons and corresponded with the increasing mRNA and protein level of TAUT. CONCLUSIONS The present study revealed that Na+/Cl(-)-coupled taurine transporter TAUT is responsible for taurine uptake in mouse cerebrocortical neurons, and that the expression of TAUT is increased with developing cerebrocortical neurons.
Collapse
Affiliation(s)
- Takuya Fujita
- Department of Biochemical Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan.
| | | | | | | | | |
Collapse
|
12
|
Saransaari P, Oja SS. Characteristics of GABA release modified by glutamate receptors in mouse hippocampal slices. Neurochem Int 2003; 43:453-9. [PMID: 12742091 DOI: 10.1016/s0197-0186(03)00034-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The major part of hippocampal innervation is glutamatergic, regulated by inhibitory GABA-releasing interneurons. The modulation of [(3)H]GABA release by ionotropic and metabotropic glutamate receptors and by nitric oxide was here characterized in superfused mouse hippocampal slices. The ionotropic glutamate receptor agonists kainate, N-methyl-D-aspartate and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate potentiated the basal GABA release. These effects were blocked by their respective antagonists 6-nitro-7-cyanoquinoxaline-2,3-dione (CNQX), dizocilpine and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-7-sulfonamide (NBQX), indicating receptor-mediated mechanisms. The NO-generating compounds S-nitroso-N-acetylpenicillamine (SNAP), sodiumnitroprusside and hydroxylamine enhanced the basal GABA release. Particularly the sodiumnitroprusside-evoked release was attenuated by the NO synthase inhibitor N(G)-nitro-L-arginine (L-NNA) and the inhibitor of soluble guanylyl cyclase 1H-(1,2,4)oxadiazolo(4,3a)quinoxalin-1-one (ODQ), indicating the involvement of the NO/cGMP pathway. This inference is corroborated by the enhancing effect of zaprinast, a phosphodiesterase inhibitor, which is known to increase cGMP levels. The K(+)-stimulated hippocampal GABA release was reduced by the groups I and III agonists of metabotropic glutamate receptors (+/-)-1-aminocyclopentane-trans-1,3-dicarboxylate (t-ACPD) and L-(+)-2-amino-4-phosphonobutyrate (L-AP4), which effects were abolished by their respective antagonists (RS)-1-aminoindan-1,5-dicarboxylate (AIDA) and (RS)-2-cyclopropyl-4-phosphonophenylglycine (CPPG), again indicating modification by receptor-mediated mechanisms.
Collapse
Affiliation(s)
- Pirjo Saransaari
- Tampere Brain Research Center, Medical School, University of Tampere, FIN 33014 Tampere, Finland.
| | | |
Collapse
|
13
|
Saransaari P, Oja SS. Ischemia-induced taurine release is modified by nitric oxide-generating compounds in slices from the developing and adult mouse hippocampus. Neurochem Res 2002; 27:395-402. [PMID: 12064355 DOI: 10.1023/a:1015551914390] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The novel neurotransmitter/neuromodulator nitric oxide (NO), which is linked to the activation of the N-methyl-D-aspartate class of glutamate receptors, has been shown to modify transmitter release in brain tissue. Release of the inhibitory amino acid taurine is also markedly enhanced by N-methyl-D-aspartate and NO-producing agents under normal conditions in the mouse hippocampus. The release of preloaded [3H]taurine from hippocampal slices from adult (3-month-old) and developing (7-day-old) mice was characterized under ischemic conditions in the presence of different NO-generating compounds, hydroxylamine, sodium nitroprusside, and S-nitroso-N-acetylpenicillamine (SNAP), using a superfusion system. The ischemia-induced taurine release at both ages was markedly enhanced by 1.0 mM nitroprusside and 1.0 mM SNAP, whereas 5.0 mM hydroxylamine was effective only in adults. The nitroprusside- and SNAP-induced releases were reduced by the inhibitors of NO synthase (nitroarginine and 7-nitroindazole) and NO-sensitive soluble guanylyl cyclase [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one], suggesting involvement of the NO/cGMP pathway. The release in ischemia in the absence of Na+ was modified by NO compounds only in adults; the 0.1 mM N-methyl-D-aspartate stimulated taurine release at both ages. The enhanced release of taurine associated with NO production could be beneficial to brain tissue under cell-damaging conditions and corroborates the neuroprotective role of this amino acid, particularly in the immature brain.
Collapse
Affiliation(s)
- Pirjo Saransaari
- Tampere Brain Research Center, Medical School, University of Tampere, Finland.
| | | |
Collapse
|
14
|
Saransaari P, Oja SS. Metabotropic glutamate receptors modulate GABA release from mouse hippocampal slices. Neurochem Res 2001; 26:175-80. [PMID: 11478745 DOI: 10.1023/a:1011055014357] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The effects of metabotropic glutamate receptor agonists on the basal and potassium (50 mM K+)-stimulated release of [3H]GABA from mouse hippocampal slices were investigated using a superfusion system. The group I agonist (1+/-)-1-aminocyclopentane-trans-1,3-dicarboxylate enhanced the basal GABA release and reduced the K+-evoked release by a mechanism antagonized by (RS)-1-aminoindan-1,5-dicarboxylate in both cases. The group II agonist (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine failed to have any effect on the basal release, but inhibited the stimulated release. This inhibition was not affected by the antagonist (2S)-2-ethylglutamate. The group III agonists L(+)-amino-4-phosphonobutyrate and O-phospho-L-serine inhibited the basal GABA release, which effects were blocked by the antagonist (RS)-2-cyclopropyl-4-phosphonophenylglycine. Moreover, the suppression of the K+-evoked release by L(+)2-amino-4-phosphonobutyrate was apparently receptor-mediated, being blocked by (RS)-2-cyclopropyl-4-phosphonophenylglycine. The results show that activation of metabotropic glutamate receptors of group I is able to potentiate the basal release of GABA, whereas activation of groups I and III receptors reduce K+-stimulated release in mouse hippocampal slices.
Collapse
Affiliation(s)
- P Saransaari
- Tampere Brain Research Center, Medical School, University of Tampere, Finland.
| | | |
Collapse
|
15
|
Abstract
The G protein-coupled metabotropic glutamate (mGlu) receptors are differentially localized at various synapses throughout the brain. Depending on the receptor subtype, they appear to be localized at presynaptic and/or postsynaptic sites, including glial as well as neuronal elements. The heterogeneous distribution of these receptors on glutamate and nonglutamate neurons/cells thus allows modulation of synaptic transmission by a number of different mechanisms. Electrophysiological studies have demonstrated that the activation of mGlu receptors can modulate the activity of Ca(2+) or K(+) channels, or interfere with release processes downstream of Ca(2+) entry, and consequently regulate neuronal synaptic activity. Such changes evoked by mGlu receptors can ultimately regulate transmitter release at both glutamatergic and nonglutamatergic synapses. Increasing neurochemical evidence has emerged, obtained from in vitro and in vivo studies, showing modulation of the release of a variety of transmitters by mGlu receptors. This review addresses the neurochemical evidence for mGlu receptor-mediated regulation of neurotransmitters, such as excitatory and inhibitory amino acids, monoamines, and neuropeptides.
Collapse
Affiliation(s)
- J Cartmell
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
| | | |
Collapse
|
16
|
Saransaari P, Oja SS. Involvement of metabotropic glutamate receptors in ischemia-induced taurine release in the developing and adult hippocampus. Neurochem Res 2000; 25:1067-72. [PMID: 11055743 DOI: 10.1023/a:1007677610714] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Metabotropic glutamate receptors have recently been envisaged as involved in both potentiation and prevention of ischemic and excitotoxic neuronal damage. The release of the inhibitory amino acid taurine is markedly enhanced in ischemia in both the immature and mature mouse hippocampus. The modulation of [3H]taurine release by metabotropic receptor agonists and antagonists was studied in hippocampal slices from developing (7-day-old) and adult (3-month-old) mice using a superfusion system. Agonists of group I, II and III metabotropic glutamate receptors generally reduced the ischemia-induced release in adult animals. In the immature hippocampus the group I agonists (S)-3,5-dihydroxyphenylglycine and (1+/-)-1-aminocyclopentane-trans-1,3-dicarboxylate, which mainly enhance neuronal excitation, potentiated initial taurine release in ischemia. Ionotropic glutamate receptor agonists also enhance the ischemia-induced taurine release in developing mice. This glutamate-activated taurine release may thus constitute an important protective mechanism against excitotoxicity in the immature hippocampus.
Collapse
Affiliation(s)
- P Saransaari
- Tampere Brain Research Center, Medical School, University of Tampere, Finland.
| | | |
Collapse
|
17
|
Saransaari P, Oja SS. Enhanced taurine release in cultured cerebellar granule cells in cell-damaging conditions. Amino Acids 2000; 17:323-34. [PMID: 10707762 DOI: 10.1007/bf01361658] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The release of taurine from cultured cerebellar granule neurons was studied in different cell-damaging conditions, including hypoxia, hypoglycemia, ischemia, oxidative stress and in the presence of free radicals. The effects of both ionotropic and metabotropic glutamate receptor agonists on the release were likewise investigated. The release of [3H]taurine from the glutamatergic granule cells was increased by K+ (50 mM) and veratridine (0.1 mM), the effect of veratridine being the greater. Hypoxia and ischemia produced an initial increase in release compared to normoxia but resulted in a diminished response to K+. Hypoglycemia, oxidative stress and free radicals enhanced taurine release, and subsequent K+ treatment exhibited a correspondingly greater stimulation. A common feature of taurine release in all the above conditions was a slow response to the stimulus evoked by K+ and particularly to that evoked by veratridine. All ionotropic glutamate receptor agonists potentiated taurine release, but only the action of kainate seemed to be receptor-mediated. Metabotropic receptor agonists of group I slightly stimulated the release. The prolonged taurine release seen in both normoxia and cell-damaging conditions may be of importance in maintaining homeostasis in the cerebellum and reducing excitability for a longer period than other neuroprotective mechanisms.
Collapse
Affiliation(s)
- P Saransaari
- Tampere Brain Research Center, University of Tampere Medical School, Finland.
| | | |
Collapse
|
18
|
Saransaari P, Oja SS. Taurine release is enhanced in cell-damaging conditions in cultured cerebral cortical astrocytes. Neurochem Res 1999; 24:1523-9. [PMID: 10591401 DOI: 10.1023/a:1021195830773] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The release of preloaded [3H]taurine from cultured cerebral cortical astrocytes was studied under various cell-damaging conditions, including hypoxia, ischemia, aglycemia and oxidative stress, and in the presence of free radicals. Astrocytic taurine release was enhanced by K+ (50 mM), veratridine (0.1 mM) and the ionotropic glutamate receptor agonist kainate (1.0 mM). Metabotropic glutamate receptor agonists had only weak effects on taurine release. Similarly to the swelling-induced taurine release the efflux in normoxia seems to be mediated mainly by DIDS-(diisothiocyanostilbene-2,2'-disulphonate) and SITS-(4-acetamido-4'-isothiocyanostilbene-2,2'-disulphonate) sensitive CI- channels, since these blockers were able to reduce both basal and K+ -stimulated release. The basal release of taurine was moderately enhanced in hypoxia and ischemia, whereas the potentiation in the presence of free radicals was marked. The small basal release from astrocytes signifies that taurine release from brain tissue in ischemia may originate from neurons rather than glial cells. On the other hand, the release evoked by K+ in hypoxia and ischemia was greater than in normoxia, with a very slow time-course. The enhanced release of the inhibitory amino acid taurine from astrocytes in ischemia may be beneficial to surrounding neurons, outlasting the initial stimulus and counteracting overexcitation.
Collapse
Affiliation(s)
- P Saransaari
- Tampere Brain Research Center, University of Tampere Medical School, Finland.
| | | |
Collapse
|